UCB (OTCMKTS:UCBJF) Shares Down 8.1% - Here's What Happened

Key Points

• Shares fell 8.1% to $300.00 on Thursday, with just 102 shares changing hands—an 88% drop from the average daily volume—after a prior close of $326.39.
• Wall Street sentiment remains positive: six analysts rate UCB as a Buy (including Overweight and Outperform calls), giving the stock an overall consensus of Buy.
• Key metrics: the 50-day moving average is $310.97 and the 200-day is $293.62, while the company shows a current ratio of 1.19, quick ratio of 0.78 and a debt-to-equity of 0.33.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s share price dropped 8.1% during trading on Thursday . The company traded as low as $300.00 and last traded at $300.00. 102 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 820 shares. The stock had previously closed at $326.39.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on UCBJF. Stephens restated an "overweight" rating on shares of UCB in a report on Thursday, January 15th. Wolfe Research assumed coverage on shares of UCB in a research report on Monday, February 23rd. They set an "outperform" rating for the company. Barclays reaffirmed an "overweight" rating on shares of UCB in a report on Tuesday, January 6th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of UCB in a research report on Monday, February 16th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy".

UCB Stock Performance

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company's fifty day moving average price is $310.97 and its 200-day moving average price is $293.62.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB's work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.